Designed
to change
the course
of autoimmune disease
Jade Biosciences is developing novel monoclonal antibody therapies to target the upstream drivers of serious autoimmune diseases with the goal of maximizing clinical activity and enabling patient friendly, infrequent subcutaneous dosing.
Our Approach
Built from disease-driving biology.
We take bold swings to develop therapies that aim to slow or stop disease progression, because we believe that should be the standard of care for autoimmune disease.